Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stuart, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stuart, K.
The Oncologist, Vol. 8, No. 5, 425–437, October 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
Hepatobiliary

Chemoembolization in the Management of Liver Tumors

Keith Stuart

Gastrointestinal and Hepatobiliary Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Correspondence: Keith Stuart, M.D., Gastrointestinal and Hepatobiliary Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. Telephone: 617-667-9235; Fax: 617-975-5665; e-mail: kstuart{at}bidmc.harvard.edu

The dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatic malignancies. Chemoembolization is a well-established technique combining intra-arterial chemotherapy with delivery of embolic agents in order to achieve an antitumor effect due to a high local concentration and prolonged dwell time of the drug, along with select ischemia. Many tumors, such as hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors, cause symptoms and death by local growth and destruction of the liver. While there are other methods capable of controlling small or isolated hepatic neoplasms, none are suitable for the majority of these patients. Chemoembolization can produce significant results in terms of tumor shrinkage in many of these patients, and there are studies to suggest a survival advantage in hepatocellular carcinoma. Toxicity, however, may be substantial, and patient selection is crucial in order to achieve the optimal benefit of this powerful technique for individual populations.

Key Words. Hepatocellular carcinoma • Chemoembolization • Liver metastases




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown
Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma
Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
M. Suzuki, Y. Sakurai, S. Hagiwara, S. Masunaga, Y. Kinashi, K. Nagata, A. Maruhashi, M. Kudo, and K. Ono
First Attempt of Boron Neutron Capture Therapy (BNCT) for Hepatocellular Carcinoma
Jpn. J. Clin. Oncol., June 19, 2007; (2007) hym039v1.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
C.-S. Lin, Y.-M. Jen, S.-Y. Chiu, J.-M. Hwang, H.-L. Chao, H.-Y. Lin, and W.-Y. Shum
Treatment of Portal Vein Tumor Thrombosis of Hepatoma Patients with Either Stereotactic Radiotherapy or Three-Dimensional Conformal Radiotherapy
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 212 - 217.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.
Advertisement